ArticleMolecular cell2021
New Type III CRISPR variant and programmable RNA targeting tool: Oh, thank heaven for Cas7-11.
Article in Molecular cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Precision gene editing: The power of CRISPR-Cas in modern genetics.Molecular therapy. Nucleic acids · 2025Review
- A review on the mechanism and potential diagnostic application of CRISPR/Cas13a system.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Review
- CRISPR RNA binding drives structural ordering that primes Cas7-11 for target cleavage.Nucleic acids research · 2025Article
- Structural basis of negative regulation of CRISPR-Cas7-11 by TPR-CHAT.Signal transduction and targeted therapy · 2024Article
- Review
- Structural insights into the regulation of Cas7-11 by TPR-CHAT.Nature structural & molecular biology · 2023Article
- Craspase is a CRISPR RNA-guided, RNA-activated protease.Science (New York, N.Y.) · 2022Article
- An Easy-to-Use Plasmid Toolset for Efficient Generation and Benchmarking of Synthetic Small RNAs in Bacteria.ACS synthetic biology · 2022Article
- Type III-A CRISPR systems as a versatile gene knockdown technology.RNA (New York, N.Y.) · 2022Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Özcan et al. (2021) and van Beljouw et al. (2021) characterize a novel Type III-E CRISPR-Cas subtype, composed of a single polypeptide with crRNA processing and sequence-specific RNA cleavage activities, that provides a new RNA knockdown tool for mammalian cells with fewer off-target effects than current technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.